Author

Nikhil Atul Shukla

Observed names: Nikhil A Shukla, Nikhil A. Shukla, Nikhil Shukla

Institution: Community Health Network

Observed institutions: Indiana University Health, Washington University in St. Louis, Community Health Network, Indiana University Indianapolis, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indiana University

ORCID: 0000-0002-0789-1323

Observed ORCID: 0000-0002-0789-1323

OpenAlex ID: A5039567220

Airway Epithelial versus Immune Cell Stat1 Function for Innate Defense against Respiratory Viral Infection

2008 · Laurie P Shornick, Audrey G Wells, et al. · The Journal of Immunology · 77

Analysis of Circulating Tumor DNA Predicts Outcomes of Short-Course Consolidation Immunotherapy in Unresectable Stage III NSCLC

2024 · Soyeong Jun, Nikhil A. Shukla, et al. · Journal of Thoracic Oncology · 39

The Story of Angiogenesis Inhibitors in Non–small-cell Lung Cancer: The Past, Present, and Future

2020 · Nikhil Atul Shukla, Melissa Noela Yan, et al. · Clinical Lung Cancer · 39

A phase 2 trial of chemotherapy plus pembrolizumab in patients with advanced non–small cell lung cancer previously treated with a PD‐1 or PD‐L1 inhibitor: Big Ten Cancer Research Consortium BTCRC‐LUN15‐029

2022 · Tareq Salous, Nikhil A. Shukla, et al. · Cancer · 32

Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small Cell Lung Cancer

2021 · Nikhil Shukla, Nasser Hanna · Lung Cancer Targets and Therapy · 32

Optimal Duration of Maintenance Checkpoint Inhibitor Therapy in Patients With Advanced NSCLC

2021 · Nikhil Shukla, Nasser Hanna, et al. · JCO Oncology Practice · 11

Association of Immune-Related Adverse Events and Efficacy Outcomes With Consolidation Pembrolizumab After Chemoradiation in Patients With Inoperable Stage III Non–Small-Cell Lung Cancer

2021 · Nikhil Atul Shukla, Sandra Althouse, et al. · Clinical Lung Cancer · 11

Analysis of circulating tumor DNA in the phase 2 BTCRC LUN 16-081 trial of consolidation nivolumab with or without ipilimumab after chemoradiation in stage III non–small cell lung cancer.

2022 · Soyeong Jun, Nikhil Shukla, et al. · Journal of Clinical Oncology · 7

Airway epithelial versus immune cell STAT‐1 function for innate defense against respiratory viral infection

2008 · Laurie P Shornick, Audrey G Wells, et al. · The FASEB Journal · 4

A phase II trial of chemotherapy plus pembrolizumab in patients with advanced NSCLC previously treated with a PD-1 or PD-L1 inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029.

2021 · Nikhil Shukla, Sandra K. Althouse, et al. · Journal of Clinical Oncology · 2

Response to Letter to the Editor

2024 · Soyeong Jun, Nikhil A. Shukla, et al. · Journal of Thoracic Oncology · 1

Practical challenges in patients with stage III NSCLC receiving checkpoint inhibitors after chemoradiation

2020 · Nikhil A Shukla, Nasser H Hanna · Lung Cancer Management · 1

Corrections: Airway Epithelial versus Immune Cell Stat1 Function for Innate Defense against Respiratory Viral Infection

2011 · Laurie P Shornick, Audrey G Wells, et al. · The Journal of Immunology · 1

A phase 1b, two-arm study of tolododekin alfa (ANK-101) in combination with an anti–PD-1/PD-L1 antibody in participants with advanced non–small cell lung cancer (NSCLC).

2026 · Thomas Urban Marron, Michael A. Pritchett, et al. · Journal of Clinical Oncology

The association between immune-related adverse events and efficacy outcomes with consolidation pembrolizumab after chemoradiation in patients with stage III NSCLC: an analysis from HCRN LUN 14-179.

2020 · Nikhil Shukla, Sandra K. Althouse, et al. · Journal of Clinical Oncology

Works count: 15

Citation count: 257

H-index: 7

I10-index: 7